R3X1 Stock Overview
A clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Opus Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.97 |
| 52 Week High | US$3.00 |
| 52 Week Low | US$0.75 |
| Beta | 0.29 |
| 1 Month Change | 7.89% |
| 3 Month Change | -16.72% |
| 1 Year Change | -60.29% |
| 3 Year Change | -68.88% |
| 5 Year Change | n/a |
| Change since IPO | -74.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| R3X1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.1% | -2.2% | -2.0% |
| 1Y | -60.3% | -15.6% | 6.9% |
Return vs Industry: R3X1 underperformed the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: R3X1 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| R3X1 volatility | |
|---|---|
| R3X1 Average Weekly Movement | 13.7% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: R3X1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: R3X1's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 14 | George Magrath | opusgtx.com |
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy.
Opus Genetics, Inc. Fundamentals Summary
| R3X1 fundamental statistics | |
|---|---|
| Market cap | €29.68m |
| Earnings (TTM) | -€26.13m |
| Revenue (TTM) | €8.05m |
3.9x
P/S Ratio-1.2x
P/E RatioIs R3X1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R3X1 income statement (TTM) | |
|---|---|
| Revenue | US$8.38m |
| Cost of Revenue | US$23.77m |
| Gross Profit | -US$15.39m |
| Other Expenses | US$11.80m |
| Earnings | -US$27.19m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | -183.63% |
| Net Profit Margin | -324.45% |
| Debt/Equity Ratio | 0% |
How did R3X1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 03:19 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Opus Genetics, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| John Newman | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |